603 Results for: created: (01/2018 to 01/2018)

People

  1. Yahalom
    Yahalom
  2. Adusumilli
    Adusumilli
  3. Zelefsky
    Zelefsky
  4. Lee
    Lee
  5. Eguchi
    Eguchi
  6. Jones
    Jones
  7. Rimner
    Rimner
  8. Travis
    Travis
  9. Yamada
    Yamada
  10. McCormick
    McCormick

Groups

  1. Department of Medicine (200)
  2. Radiation Oncology, Department of (129)
  3. Solid Tumor Oncology Division (123)
  4. Survivorship Research (122)
  5. Surgery (121)
  6. GSK Faculty (107)
  7. Sloan Kettering Institute Postdocs (99)
  8. Center for Hematologic Malignancies (74)
  9. Hematologic Malignancies, Division of (65)
  10. Epidemiology and Biostatistics (64)
Formats
  1. Journal Article (322)
  2. Meeting Abstract (139)
  3. Book Section (138)
  4. Book Whole (2)
  5. Conference Paper (1)
  6. Editorial (1)
Groups
  1. Department of Medicine (200)
  2. Radiation Oncology, Department of (129)
  3. Solid Tumor Oncology Division (123)
  4. Survivorship Research (122)
  5. Surgery (121)
  6. GSK Faculty (107)

More Groups

People
  1. Joachim Yahalom (32)
  2. Prasad Adusumilli (27)
  3. Michael Zelefsky (24)
  4. Nancy Lee (20)
  5. David Jones (19)
  6. Takashi Eguchi (19)

More People

Years
  1. 2018 (65)
  2. 2017 (371)
  3. 2016 (4)
  4. 2015 (1)
  5. 2014 (10)
  6. 2013 (4)

More Years

Publications
  1. Journal of Thoracic Oncology (53)
  2. Cancer: Principles and Practice of Oncology. 6th ed (27)
  3. Neuro-Oncology (27)
  4. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 9th ed (25)
  5. Journal of Clinical Oncology (12)
  6. Clinical Cancer Research (11)

More Publications

Publishers
  1. Elsevier Inc. (107)
  2. Lippincott Williams & Wilkins (56)
  3. Elsevier Science, Inc. (36)
  4. Oxford University Press (34)
  5. Springer (34)
  6. Wolters Kluwer Health | Lippincott Williams & Wilkins (33)

More Publishers

Results (603)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Toxicity of single agent carmustine versus carmustine plus bevacizumab in patients with recurrent or progressive high grade gliomas
    Meeting Abstract

    Yerram, P.; Reiss, S.; Modelevsky, L.; Gavrilovic, I.; Kaley, T.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Impact of early integration of palliative care on health care proxy (HCP) documentation by patients with myelodysplastic syndromes (MDS)
    Meeting Abstract

    Desai, A. V.; Chow, K.; Wan, P. J.; O'shea, D.; Ranaghan, C.; Anderson, K.; Kramer, D.; Goldberg, J. I.; Rawlins, R.; Koczela, E.; more...
    Leukemia Research (2017)

    Fulltext@MSK | Save
  • AG-120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: Updated results from the phase 1 non-enhancing glioma population
    Meeting Abstract

    Mellinghoff, I. K.; Touat, M.; Maher, E.; De La Fuente, M.; Cloughesy, T. F.; Holdhoff, M.; Cote, G. M.; Burris, H.; Janku, F.; Huang, R.; more...
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Phase 2 study of selinexor in patients with myelodysplastic syndromes refractory to hypomethylating agents: Interim report
    Meeting Abstract

    Klimek, V. M.; Coleman, M.; Alvarez, K.; Sen, F.; Pichardo, J.; Kashyap, T.; Klebanov, B.
    Leukemia Research (2017)

    Fulltext@MSK | Save
  • Robust patient-derived xenografts (PDX) capture the disease fidelity of chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML)
    Meeting Abstract

    Balasis, M. E.; Yoshimi, A.; Vedder, A.; Feldman, K.; Ma, Y.; Zhang, H.; Lee, S. C. W.; Letson, C.; Niyongere, S.; Lu, S. X.; more...
    Leukemia Research (2017)

    Fulltext@MSK | Save
  • Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab [DUR]) in patients with bevacizumab (BEV)-refractory recurrent glioblastoma (GBM)
    Meeting Abstract

    Reardon, D.; Kaley, T.; Dietrich, J.; Clarke, J. L.; Dunn, G. P.; Lim, M.; Cloughesy, T.; Gan, H. K.; Park, A.; Schwarzenberger, P.; more...
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • Lanreotide in patients with lung neuroendocrine tumors: The randomized double-blind placebo-controlled international phase 3 SPINET study
    Meeting Abstract

    Reidy-Lagunes, D.; Kulke, M.; Wolin, E.; Singh, S.; Ferone, D.; Hoersch, D.; Mirakhur, B.; Hoffmanns, P.; Houchard, A.; Caplin, M.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Comparability of the relative survival metrics among lung cancer patients and general population
    Meeting Abstract

    Tan, K. S.; Eguchi, T.; Adusumilli, P.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Appropriate endpoint for stage I NSCLC: Correlations of long-term survival with disease-free and recurrence-free survival
    Meeting Abstract

    Tan, K. S.; Eguchi, T.; Adusumilli, P.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • An analysis of the transcriptional response of myelodysplastic syndrome stem cells to therapy at single-cell resolution
    Meeting Abstract

    Chung, S.; Vijay, P.; Klimek, V.; Mason, C.; Park, C.
    Leukemia Research (2017)

    Fulltext@MSK | Save